TARS,PASG,PHAT,MIRM Stock Quote

TARS [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	17.00%	Shs Outstand	21.05M	Perf Week	-18.50%
Market Cap	644.34M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	0.00%	Shs Float	13.52M	Perf Month	-18.24%
Income	-	PEG	-	EPS next Q	-0.66	Inst Own	61.70%	Short Float	2.58%	Perf Quarter	32.63%
Sales	-	P/S	-	EPS this Y	-254.10%	Inst Trans	-	Short Ratio	3.77	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-14.90%	ROA	-	Target Price	41.50	Perf Year	-
Cash/sh	4.10	P/C	7.47	EPS next 5Y	-	ROE	-	52W Range	15.32 - 63.69	Perf YTD	-25.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-51.94%	Beta	-
Dividend %	-	Quick Ratio	14.50	Sales past 5Y	-	Gross Margin	-	52W Low	99.74%	ATR	3.57
Employees	12	Current Ratio	14.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.98	Volatility	12.37% 10.03%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.47	Prev Close	33.13
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	92.49K	Price	30.61
Recom	1.20	SMA20	-18.88%	SMA50	-24.34%	SMA200	-8.32%	Volume	43,175	Change	-7.61%

Nov-10-20

Initiated

Raymond James

Strong Buy

$39

Nov-10-20

Initiated

Ladenburg Thalmann

Buy

$42

Nov-10-20

Initiated

Jefferies

Buy

$35

Nov-10-20

Initiated

BofA Securities

Buy

$33

Jan-19-21 08:30AM	Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel GlobeNewswire
Jan-18-21 08:43AM	Tarsus Pharmaceuticals (NASDAQ:TARS) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-07-21 09:24AM	Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer GlobeNewswire +5.23%
Jan-05-21 05:00PM	Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference GlobeNewswire
Dec-23-20 07:00AM	Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03 GlobeNewswire
Dec-21-20 07:00AM	Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index GlobeNewswire -11.00%
Nov-19-20 03:24PM	Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors GlobeNewswire +7.78%
Nov-13-20 07:35PM	Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +10.16%
Oct-20-20 04:05PM	Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares GlobeNewswire
Oct-16-20 06:05PM	Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day Barrons.com
Oct-15-20 08:35PM	Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering GlobeNewswire

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

PASG [NASD]

Passage Bio, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.56	Insider Own	0.60%	Shs Outstand	45.50M	Perf Week	10.34%
Market Cap	1.00B	Forward P/E	-	EPS next Y	-2.92	Insider Trans	-0.42%	Shs Float	23.39M	Perf Month	-6.54%
Income	-86.40M	PEG	-	EPS next Q	-0.70	Inst Own	70.30%	Short Float	8.41%	Perf Quarter	-11.76%
Sales	-	P/S	-	EPS this Y	-257.30%	Inst Trans	3.44%	Short Ratio	4.30	Perf Half Y	18.69%
Book/sh	7.45	P/B	2.61	EPS next Y	-5.10%	ROA	-	Target Price	28.50	Perf Year	-5.68%
Cash/sh	6.49	P/C	2.99	EPS next 5Y	-	ROE	-	52W Range	8.09 - 38.23	Perf YTD	-24.01%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-49.18%	Beta	-
Dividend %	-	Quick Ratio	18.30	Sales past 5Y	-	Gross Margin	-	52W Low	140.17%	ATR	1.70
Employees	20	Current Ratio	18.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.53	Volatility	9.73% 8.00%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-116.90%	Profit Margin	-	Rel Volume	0.89	Prev Close	19.96
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 03 BMO	Payout	-	Avg Volume	457.43K	Price	19.43
Recom	1.70	SMA20	-3.94%	SMA50	-16.10%	SMA200	-5.75%	Volume	408,478	Change	-2.66%

Mar-04-21

Upgrade

Goldman

Neutral → Buy

$28 → $30

Feb-04-21

Initiated

Guggenheim

Buy

$25

Jan-25-21

Initiated

Wedbush

Outperform

$26

Jan-04-21

Upgrade

JP Morgan

Neutral → Overweight

$25 → $35

Dec-11-20

Initiated

Citigroup

Neutral

$28

Aug-14-20

Downgrade

JP Morgan

Overweight → Neutral

$25

Jun-25-20

Downgrade

Goldman

Buy → Neutral

$28

Mar-25-20

Initiated

Chardan Capital Markets

Buy

$30

Mar-24-20

Initiated

JP Morgan

Overweight

$25

Mar-24-20

Initiated

Goldman

Buy

$27

Mar-24-20

Initiated

Cowen

Outperform

Mar-03-21 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights GlobeNewswire
06:30AM	Passage Bio Inc to Host Earnings Call ACCESSWIRE
Mar-02-21 04:01PM	Passage Bio to Participate in Upcoming March Investor Conferences GlobeNewswire
Feb-24-21 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021 GlobeNewswire
Feb-19-21 07:00AM	Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors GlobeNewswire -5.41%
Feb-08-21 07:00AM	FDA Clears IND Application for Passage Bios Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options GlobeNewswire
Feb-04-21 12:04PM	Why Guggenheim Is Bullish On Passage Bio Benzinga +6.17%
10:03AM	Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2021 Benzinga
Jan-28-21 07:00AM	Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations GlobeNewswire
03:00AM	What Type Of Shareholders Make Up Passage Bio, Inc.'s (NASDAQ:PASG) Share Registry? Simply Wall St.
Jan-22-21 02:22PM	Here's Why Shares of Passage Bio Dropped Today Motley Fool -13.19%
Jan-21-21 07:48PM	Passage Bio Announces Pricing of Public Offering GlobeNewswire -16.44%
Jan-19-21 04:06PM	Passage Bio Announces Launch of Proposed Public Offering GlobeNewswire
07:00AM	Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25 GlobeNewswire
Jan-13-21 10:25AM	J.P. Morgan Predicts 30%-Plus Rally for These 2 Stocks TipRanks
Jan-11-21 07:00AM	Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021 GlobeNewswire
Jan-04-21 04:01PM	Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire +9.97%
07:00AM	Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis GlobeNewswire
Dec-16-20 08:00AM	Passage Bio Announces Gene Therapy Manufacturing Research and Development Site GlobeNewswire +10.69%
Dec-15-20 11:10PM	Is PASG A Good Stock To Buy Now? Insider Monkey
Dec-11-20 08:11AM	The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga
Dec-10-20 04:01PM	Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis GlobeNewswire
Dec-07-20 07:00AM	Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products GlobeNewswire
Nov-24-20 03:55AM	Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +5.18%
Nov-23-20 04:01PM	Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-11-20 04:30PM	Passage Bio Highlights University of Pennsylvanias Gene Therapy Programs Newly Published Research to Prevent Toxicity Associated with Gene Therapy GlobeNewswire
07:00AM	Passage Bio to Participate in Upcoming November Investor Conferences GlobeNewswire
Nov-10-20 07:00AM	Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
Nov-09-20 07:00AM	Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1 GlobeNewswire
Nov-04-20 07:00AM	Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020 GlobeNewswire
Oct-28-20 07:00AM	Passage Bios PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease GlobeNewswire
Oct-26-20 07:00AM	Passage Bios PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis GlobeNewswire
Oct-14-20 08:30AM	Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session Zacks
Oct-13-20 04:30PM	Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic GlobeNewswire +5.41%
Oct-06-20 07:00AM	Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-25-20 07:00AM	Passage Bio to Participate in Upcoming October Investor Conferences GlobeNewswire +6.55%
Sep-17-20 07:00AM	Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program GlobeNewswire
Sep-03-20 08:00AM	Passage Bio to Participate in Citis 15th Annual BioPharma Virtual Conference GlobeNewswire
Aug-26-20 02:58PM	Have Insiders Been Buying Passage Bio, Inc. (NASDAQ:PASG) Shares This Year? Simply Wall St.
Aug-13-20 07:00AM	Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
Aug-07-20 04:01PM	Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020 GlobeNewswire +12.99%
Jun-26-20 08:00AM	Passage Bio Added to Russell 2000 Index GlobeNewswire -18.97%
Jun-04-20 11:17AM	Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio Zacks +5.49%
08:00AM	Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-28-20 08:35AM	Companies Like Passage Bio (NASDAQ:PASG) Are In A Position To Invest In Growth Simply Wall St.
May-21-20 08:00AM	Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis GlobeNewswire +7.80%
May-12-20 05:00PM	Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting GlobeNewswire
May-11-20 07:00AM	Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
May-07-20 07:30AM	Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania GlobeNewswire
May-04-20 08:00AM	Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020 GlobeNewswire
Apr-21-20 08:00AM	FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis GlobeNewswire -7.44%
Apr-08-20 08:00AM	Passage Bio to Present at 19th Annual Needham Healthcare Conference GlobeNewswire
Mar-27-20 08:00AM	Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day GlobeNewswire -8.07%
Mar-09-20 04:30PM	Passage Bio Announces Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -9.41%
Mar-05-20 08:00AM	Passage Bio Appoints Athena Countouriotis to Board of Directors GlobeNewswire
Feb-27-20 07:25PM	Passage Bio Announces Pricing of Initial Public Offering GlobeNewswire

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quigley Jill M.	Chief Operating Officer	Jan 20	Sale	30.01	1,300	39,011	295,284	Jan 22 05:54 PM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

PHAT [NASD]

Phathom Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-6.81	Insider Own	17.16%	Shs Outstand	25.92M	Perf Week	-4.06%
Market Cap	1.44B	Forward P/E	-	EPS next Y	-3.76	Insider Trans	-4.97%	Shs Float	9.71M	Perf Month	3.32%
Income	-173.40M	PEG	-	EPS next Q	-1.01	Inst Own	79.50%	Short Float	4.87%	Perf Quarter	-1.76%
Sales	-	P/S	-	EPS this Y	84.80%	Inst Trans	12.36%	Short Ratio	3.16	Perf Half Y	26.60%
Book/sh	6.03	P/B	7.33	EPS next Y	-10.30%	ROA	-69.00%	Target Price	54.50	Perf Year	16.94%
Cash/sh	6.94	P/C	6.36	EPS next 5Y	-	ROE	-88.70%	52W Range	22.06 - 64.54	Perf YTD	32.96%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-31.56%	Beta	-
Dividend %	-	Quick Ratio	8.20	Sales past 5Y	-	Gross Margin	-	52W Low	100.23%	ATR	2.56
Employees	25	Current Ratio	8.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.50	Volatility	7.51% 5.15%
Optionable	Yes	Debt/Eq	0.30	EPS Q/Q	52.60%	Profit Margin	-	Rel Volume	0.73	Prev Close	45.87
Shortable	Yes	LT Debt/Eq	0.26	Earnings	-	Payout	-	Avg Volume	149.65K	Price	44.17
Recom	2.00	SMA20	-1.41%	SMA50	10.00%	SMA200	12.76%	Volume	109,222	Change	-3.71%

Feb-17-21

Initiated

BMO Capital Markets

Outperform

$63

Feb-02-21

Initiated

Guggenheim

Buy

$60

Jun-26-20

Downgrade

Goldman

Neutral → Sell

$34

Nov-20-19

Initiated

Evercore ISI

Outperform

Nov-19-19

Initiated

Needham

Buy

$40

Nov-19-19

Initiated

Jefferies

Buy

$32

Nov-19-19

Initiated

Goldman

Neutral

$32

Feb-17-21 10:12AM	Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021 Benzinga
Feb-02-21 10:07AM	Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021 Benzinga +11.07%
Jan-19-21 08:30AM	Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial GlobeNewswire
Dec-16-20 06:43PM	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -8.40%
Dec-15-20 04:01PM	Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock GlobeNewswire +13.05%
Dec-14-20 08:30AM	Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD) GlobeNewswire
Dec-08-20 09:00AM	Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher Zacks
Dec-02-20 11:33PM	Here is What Hedge Funds Think About Phathom Pharmaceuticals, Inc. (PHAT) Insider Monkey
Nov-30-20 04:05PM	Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial GlobeNewswire
Nov-27-20 08:00AM	Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences GlobeNewswire
Nov-19-20 04:05PM	Phathom Pharmaceuticals to Host Virtual Investor Day GlobeNewswire
Nov-13-20 04:05PM	Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +5.63%
Nov-10-20 04:05PM	Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials GlobeNewswire
Nov-04-20 04:05PM	Arcutis Announces Appointment of Terrie Curran to Board of Directors GlobeNewswire
Sep-09-20 08:30AM	Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire +7.00%
Aug-06-20 08:30AM	Phathom Pharmaceuticals Reports Second Quarter 2020 Results GlobeNewswire
Jul-13-20 08:30AM	Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer GlobeNewswire
Jun-15-20 08:30AM	Phathom Pharmaceuticals Provides Clinical Trial Status Update GlobeNewswire -12.74%
Jun-12-20 10:25PM	Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT) Insider Monkey
May-28-20 04:30PM	Phathom Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -6.72%
May-12-20 08:30AM	Phathom Pharmaceuticals Reports First Quarter 2020 Results GlobeNewswire
Apr-09-20 04:30PM	Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-19-20 08:30AM	Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates GlobeNewswire
Feb-25-20 04:35PM	Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020 GlobeNewswire
Jan-16-20 09:00AM	Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund PR Newswire +5.16%
Jan-06-20 08:30AM	Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer Business Wire +9.57%
Dec-23-19 08:30AM	Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection Business Wire +15.59%
Dec-02-19 08:30AM	Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition Business Wire
08:30AM	Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis Business Wire
Nov-26-19 08:30AM	Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference TEST Business Wire Releases
08:30AM	Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference Business Wire
Nov-25-19 08:30AM	Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update TEST Business Wire Releases
08:30AM	Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Nov-13-19 04:05PM	Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference Business Wire
Oct-29-19 04:05PM	Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-25-19 05:10PM	Phathom Pharmaceuticals Rises Almost 30% After $182 Million Bloomberg
Oct-24-19 08:25PM	Phathom Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nabulsi Azmi	Chief Operating Officer	Mar 02	Sale	45.90	9,127	418,928	794,700	Mar 03 08:20 PM
Nabulsi Azmi	Chief Operating Officer	Mar 01	Sale	45.85	5,373	246,362	803,827	Mar 03 08:20 PM
Socks David A	Director	Feb 23	Sale	43.74	4,984	217,991	1,435,945	Feb 23 06:14 PM
Socks David A	Director	Feb 22	Sale	45.66	20,140	919,587	1,440,929	Feb 23 06:14 PM
Socks David A	Director	Feb 19	Sale	47.18	44,876	2,117,034	1,461,069	Feb 23 06:14 PM
Nabulsi Azmi	Chief Operating Officer	Feb 02	Sale	40.97	9,084	372,156	809,200	Feb 03 04:05 PM
Nabulsi Azmi	Chief Operating Officer	Feb 01	Sale	38.09	5,416	206,285	818,284	Feb 03 04:05 PM
Socks David A	Director	Jan 12	Sale	36.07	27,165	979,795	1,532,945	Jan 13 05:07 PM
Socks David A	Director	Jan 11	Sale	34.92	12,835	448,243	1,560,110	Jan 13 05:07 PM
Socks David A	Director	Dec 17	Sale	40.74	48,212	1,964,376	1,572,945	Dec 18 08:01 PM
Socks David A	Director	Dec 16	Sale	47.53	31,446	1,494,519	1,621,157	Dec 18 08:01 PM
Nabulsi Azmi	Chief Operating Officer	Dec 02	Sale	45.26	7,302	330,513	838,200	Dec 03 06:01 PM
Nabulsi Azmi	Chief Operating Officer	Dec 01	Sale	44.20	7,198	318,176	845,502	Dec 03 06:01 PM
Socks David A	Director	Nov 11	Sale	38.97	6,877	268,021	1,652,603	Nov 12 04:13 PM
Socks David A	Director	Nov 10	Sale	41.69	12,681	528,672	1,659,480	Nov 12 04:13 PM
Socks David A	Director	Nov 09	Sale	42.33	10,784	456,506	1,676,562	Nov 12 04:13 PM
Nabulsi Azmi	Chief Operating Officer	Nov 02	Sale	36.83	14,500	534,026	852,700	Nov 03 06:40 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 01	Buy	24.86	117,600	2,923,642	3,825,008	Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Mar 31	Buy	24.55	30,600	751,264	3,707,408	Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Mar 27	Buy	24.60	30,000	738,000	3,676,808	Mar 31 05:02 PM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

MIRM [NASD]

Mirum Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.43	Insider Own	0.40%	Shs Outstand	25.13M	Perf Week	-12.98%
Market Cap	485.93M	Forward P/E	-	EPS next Y	-3.82	Insider Trans	6.68%	Shs Float	9.89M	Perf Month	-14.22%
Income	-84.00M	PEG	-	EPS next Q	-0.72	Inst Own	82.50%	Short Float	6.45%	Perf Quarter	-31.76%
Sales	-	P/S	-	EPS this Y	-202.90%	Inst Trans	15.94%	Short Ratio	2.94	Perf Half Y	-31.81%
Book/sh	4.78	P/B	3.41	EPS next Y	-15.80%	ROA	-54.50%	Target Price	-	Perf Year	-3.50%
Cash/sh	4.49	P/C	3.63	EPS next 5Y	-	ROE	-61.90%	52W Range	9.14 - 27.43	Perf YTD	-6.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-40.61%	Beta	-
Dividend %	-	Quick Ratio	7.40	Sales past 5Y	-	Gross Margin	-	52W Low	78.23%	ATR	1.06
Employees	67	Current Ratio	7.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.45	Volatility	5.79% 5.52%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-30.50%	Profit Margin	-	Rel Volume	1.28	Prev Close	17.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	217.03K	Price	16.29
Recom	1.40	SMA20	-17.25%	SMA50	-14.72%	SMA200	-18.16%	Volume	278,460	Change	-8.99%

Aug-07-20

Upgrade

Raymond James

Outperform → Strong Buy

$28 → $48

Aug-03-20

Initiated

H.C. Wainwright

Buy

$52

Jul-31-20

Initiated

Piper Sandler

Overweight

$77

Jun-25-20

Initiated

Robert W. Baird

Outperform

$30

Aug-12-19

Initiated

ROTH Capital

Buy

$33

Aug-12-19

Initiated

Raymond James

Outperform

$28

Aug-12-19

Initiated

Guggenheim

Buy

$18

Aug-12-19

Initiated

Evercore ISI

Outperform

Aug-12-19

Initiated

Citigroup

Buy

$21

Feb-22-21 09:00AM	Mirum Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-10-21 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-08-21 10:12AM	Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2021 Benzinga +10.05%
Feb-01-21 09:00AM	Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome Business Wire
Jan-24-21 09:00AM	Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign Business Wire
Jan-14-21 09:00AM	Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis Business Wire -5.24%
Jan-12-21 09:00AM	Mirum Pharmaceuticals Provides Corporate Update Business Wire +5.04%
Jan-08-21 06:17PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-04-21 08:30AM	Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 Business Wire
Dec-30-20 02:45AM	What Kind Of Shareholders Own Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)? Simply Wall St. -6.86%
Dec-22-20 08:55AM	Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher Zacks
Dec-14-20 09:00PM	Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -5.70%
07:00AM	Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock Business Wire
Dec-10-20 10:33PM	Is MIRM A Good Stock To Buy Now? Insider Monkey
07:41PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-09-20 09:00AM	Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement Business Wire
Dec-07-20 09:00AM	Mirum Pharmaceuticals Announces Virtual Investor Day 2020 Business Wire
Nov-30-20 08:30AM	Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2 Business Wire +5.39%
Nov-23-20 09:30AM	Mirum Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Nov-15-20 06:00PM	Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat Business Wire
Nov-13-20 08:10AM	Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting Business Wire +6.02%
Nov-12-20 09:00AM	Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day Business Wire +5.23%
Nov-10-20 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-05-20 08:30AM	Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia Business Wire
Nov-02-20 08:30AM	Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Business Wire
Oct-26-20 08:30AM	Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020 Business Wire -5.09%
Oct-15-20 08:55AM	Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States PR Newswire
08:45AM	Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States Business Wire
Oct-14-20 10:29AM	Raymond James Says These 3 Stocks Could Surge Over 100% From Current Levels TipRanks
Oct-13-20 04:05PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-11-20 04:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:00AM	Mirum Pharmaceuticals to Present at Investor Conferences in September Business Wire
Sep-01-20 09:00AM	Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program Business Wire -7.97%
Aug-29-20 08:45AM	Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020 Business Wire
Aug-11-20 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
09:42AM	We're Hopeful That Mirum Pharmaceuticals (NASDAQ:MIRM) Will Use Its Cash Wisely Simply Wall St.
09:37AM	Companies Like Mirum Pharmaceuticals (NASDAQ:MIRM) Are In A Position To Invest In Growth Simply Wall St.
Aug-07-20 04:05PM	Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference Business Wire +7.53%
Aug-06-20 04:05PM	Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates Business Wire +5.10%
Jul-10-20 05:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-22-20 02:06PM	Hedge Funds Are Nibbling On Mirum Pharmaceuticals, Inc. (MIRM) Insider Monkey
Jun-11-20 04:10PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -9.48%
Jun-02-20 08:30AM	Mirums Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis Business Wire
May-29-20 10:05AM	Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference Business Wire
May-11-20 05:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +9.03%
May-07-20 04:05PM	Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates Business Wire
Apr-28-20 04:19PM	Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer Business Wire
Mar-12-20 04:02PM	Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire -6.99%
Feb-18-20 04:01PM	Mirum Pharmaceuticals to Participate at Four Upcoming Conferences Business Wire
Jan-16-20 09:00AM	Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund PR Newswire +15.15%
Jan-14-20 09:00AM	Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer Business Wire -5.11%
Jan-08-20 08:15PM	Mirum Pharmaceuticals Announces Pricing of Public Offering Business Wire -7.33%
Dec-24-19 10:40AM	Is Mirum Pharmaceuticals, Inc. (MIRM) A Good Stock To Buy? Insider Monkey
Dec-17-19 07:56AM	The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga
Dec-16-19 08:00AM	Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat Business Wire +110.99%
Dec-13-19 04:28PM	Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast Business Wire
Nov-25-19 08:30AM	Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference TEST Business Wire Releases
08:30AM	Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference Business Wire
Nov-08-19 08:05AM	Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases Business Wire
Nov-06-19 04:05PM	Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update Business Wire
Oct-28-19 04:05PM	Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer Business Wire
08:30AM	Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Business Wire
Oct-21-19 10:15AM	Durability of Treatment Effect of Mirum Pharmaceuticals Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019 Business Wire
Oct-01-19 04:30PM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019 Business Wire
Sep-26-19 08:35AM	Company Profile for Mirum Pharmaceuticals Business Wire
08:30AM	Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference Business Wire
Aug-28-19 04:01PM	Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update Business Wire
Aug-12-19 09:57AM	Mirum Pharma's Lead Asset Has $450M Sales Opportunity, Raymond James Says In Bullish Initiation Benzinga
Jul-17-19 06:33PM	Mirum Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire
Jul-15-19 10:10AM	IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China Benzinga
Jul-12-19 12:10PM	Mirum Pharmaceuticals IPO: What You Need To Know Benzinga

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tucker Edwin Jonathan	Chief Medical Officer	Dec 28	Option Exercise	7.70	4,167	32,086	36,442	Dec 29 04:24 PM
Clements Ian	Chief Financial Officer	Dec 23	Buy	18.61	2,470	45,975	7,841	Dec 28 04:12 PM
Peetz Christopher	President and CEO	Dec 23	Buy	18.70	5,000	93,480	201,570	Dec 28 04:06 PM
Tucker Edwin Jonathan	Chief Medical Officer	Oct 30	Option Exercise	7.70	25,000	192,500	31,000	Nov 03 05:09 PM
Tucker Edwin Jonathan	Chief Medical Officer	Mar 20	Buy	11.90	2,500	29,740	6,000	Mar 23 04:47 PM
Tucker Edwin Jonathan	Chief Medical Officer	Mar 19	Buy	9.91	2,000	19,818	3,500	Mar 23 04:47 PM

open in screener | open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience